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P rimary cutaneous melanomas are typically catego-rized by clinicohistopathologic features, namely, su-perficial spreading melanoma (SSM), lentigo maligna
melanoma, acral lentiginous melanoma, and nodular mela-
noma (NM).They have also been subcategorized based on the
degree of sun damage: chronic sun damage, intermittent sun
damage, or nonchronic sun damage.1 Molecular studies have
revealed BRAF, NRAS, and KIT are the common and major
growth-promoting mutated genes involved in melanoma
pathogenesis.1-5 HRAS and GNAQ mutations have been re-
ported in cutaneous melanoma, but they are much less
frequent.5,6 Several publications have shown that BRAF and
NRAS mutations are present in up to 50% and 20%, respec-
tively, of cutaneousmelanomas.2,3 BRAF andNRAS aremore
prevalent in the vertical growthphase and in fast-growing cu-
taneousmelanomas, especiallyNRAS.7,8 Thesemutatedgenes
canbepartially correlatedwith the current clinicohistopatho-
logic classification system in which BRAF mutation is more
likely to be present in SSM, andNRAS in NM.2,3BRAF andKIT
mutations have also been shown to predominate in melano-
masarising in intermittently sundamagedandchronically sun
damaged skin, respectively.1,4 While there is a correlation of
the driving mutation with the current classification scheme,
the correlation overall is modest, and for a considerable frac-
tion of melanomas, the growth-promoting mutation is un-
known.
Growth-promoting mutations activate the mitogen-
activated protein kinase/extracellular signal-regulated ki-
nase (MAPK/ERK) pathway, which promotes DNA replica-
tion,cell cycleprogression,and,ultimately, tumorgrowth.Only
certain mutations seem to be able to activate these proteins.
All the reportedNRASgenemutationsare located inexon2and
exon 3 (previously termed exon 1 and exon 2); most are pres-
ent in exon3at codon61,where the commonaminoacids sub-
stitutions are Q61K and Q61R. BRAF gene mutations are lo-
cated in codon 600, usually converting valine to glutamic
acid.2,3 Mutations inKIT aremorewidely distributed and fre-
quently affect exons 11 and 13, but mutations in exon 17 and
18havebeen reported. Theusual amino acid substitutions for
KIT are L576P, K642E, D816H, and A829P.1,4 Although HRAS
andGNAQmutations aremore likely to be found in Spitz nevi
and blue nevi, respectively, there have been 3 reported cases
ofHRAS (Q61H/L/K)mutations and 2 reported cases ofGNAQ
(Q209L/P) mutations in cutaneous melanoma.5,6 In particu-
lar, GNAQ mutations were present within melanomas with
chronically sun-damaged areas.6
IMPORTANCE Mutations driving melanoma growth have diagnostic, prognostic, and
therapeutic implications. Traditional classification systems do not correlate optimally with
underlying melanoma growth–promotingmutations. Our objective was to determine
whether unique dermoscopic growth patterns directly correlate with driving mutations.
OBSERVATIONS We evaluated common driving mutations in 4 different dermoscopic patterns
(rhomboidal, negative pigmented network, polygonal, and dark homogeneous streaks) of
primary cutaneous melanomas; 3 melanomas per pattern were tested. Three of the 4
patterns lacked commonmutations in BRAF, NRAS, KIT, GNAQ, andHRAS. One pattern, the
dark homogeneous streaks pattern, had unique KITmutations in the second catalytic domain
of KIT in exon 17 for all 3 samples tested. Two tumors with the dark homogeneous streaks
pattern turned out to be different primary melanomas from the same patient and had
different sequencemutations but had an impact on the same KIT domain.
CONCLUSIONS AND RELEVANCE While future study is required, these results havemultiple
implications. (1) The underlying melanoma-driving mutations may give rise to specific
dermoscopic growth patterns, (2) BRAF/NRASmutations in early melanomasmay not be as
common as previously thought, and (3) patients may be predisposed to developing specific
driving mutations giving rise to melanomas or nevi of similar growth patterns.
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While the commonly identified melanoma growth–
promoting mutations all drive the MAPK/ERK pathway, they
also interact with other regulatory pathways, which may al-
ter their growth pattern. Dermoscopy allows for improved vi-
sualizationof tumor structures and increaseddiagnosisof thin
or early cutaneous melanomas. We hypothesize that tumors
with similar “dermoscopic” surface growthpatternswill have
similar underlining growth-promotingmutations and that ul-
timatelydermoscopicgrowthpatternsmayserve tobetter seg-
regate melanoma subtypes and genotypes than the current
classification system.
Reports of Cases
Study Set
Our study was approved by the institutional review board of
the University of Miami. A collection of 182 dermoscopic im-
ages of melanomas from the University of Miami Melanoma
Program and Plantation Cutaneous and Surgery Clinic from
2000 to 2011 were reviewed by 3 of us (M.I.S., H.S.R., and
J.M.G.). Primary cutaneous melanomas with similar dermo-
scopic features were grouped together based on dermoscopy
features fromArgenziano et al,9 Pizzichetta et al,10 Keir,11 and
our own experience. At least 10 different primary dermo-
scopicgrowthpatternswerenoted, includingdisorganized fine
network,9 epidermal crease sparing, gray-dotted regression,9
homogeneous,9 multicolor multicomponent,9 perifollicular
pigmented,9 rhomboidal (grayish brown pigmentation sur-
rounding the follicular ostia),9 polygonal (irregular grayish
brown pigmentation outlining the limits between hair fol-
licles forming multiple-sided figures),11 negatively pig-
mented network (light areas forming the “cords” of the net-
work and darker areas filling the holes),10 and dark
homogeneous streaks patterns (structureless, brownishblack
pigmentationwithbulbousprojectionsor streaks at theedge)9
(Figures 1, 2, and 3 and eFigure 1 and eFigure 2 in Supple-
ment). Four of the 10melanomapatternswere selected for ge-
netic analysis based on the dermoscopic pattern being rela-
tively uniform throughout the entire lesion (reducing the
chance of differentmutations in different areas of the lesion)
and the availability of at least 3 cases with adequate tissue in
the formalin-fixed, paraffin-embedded (FFPE) blocks. The 4
patterns selected for genetic analysis were the rhomboidal
(eFigure 1 [Supplement]), negatively pigmented network
(Figure 2), polygonal (eFigure 2 [Supplement]), and dark ho-
mogeneous streaks pattern (Figure 3). The Breslow thick-
nesses ranged from in situ to 1.1 mm in the lesions tested. In-
dividually, the depths of the rhomboidal, polygonal pattern,
negativelypigmentednetwork,anddarkhomogeneousstreaks
patterns ranged from in situ to 0.55 mm, in situ to 0.32 mm,
0.4 to 0.46 mm, and 0.75 to 1.1 mm, respectively (eTable 1
[Supplement]).Histologic reportsclassified the lesionsasmela-
noma in situ and melanoma for the rhomboid and polygonal
patterns. For the negatively pigmented network and dark ho-
mogeneous streaks patterns, the histologic reports classified
the lesions as melanoma and superficial spreading mela-
noma, respectively. An associated nevus precursor was not
noted for any of the tested melanomas. The specific com-
ments on themorphologic characteristics for eachpattern are
noted in eTable 1 (Supplement).
Genetic Testing
Three cases were analyzed for each of the 4 specific dermo-
scopic growth patterns chosen for study. All of the caseswere
from unique patients except for 2 of the cases of dark homo-
geneous streaks pattern,which turned out to be different pri-
mary tumors from the same patient. Tomaximally enrich the
specimens for tumorDNA, the slidesweredeparaffinized and
immunohistochemically stained with a cocktail of anti–
melan A (Abcam) and anti-S100 (Biocare Medical). NovaRed
(VectorLaboratories)wasusedasachromagen.Melanomacells
and keratinocytes (as controls) from each case were specifi-
cally and separately captured within different 0.5-mL tubes
using theLaserCapturemicrodissection system (LeicaMicro-
systems). Each sample went through DNA extraction using a
QIAamp kit (QIAGEN) and amplification with a REPLI-g kit
(QIAGEN). Polymerase chain reactions (PCRs) for all the
sampleswereperformedusingaKODHotStartMasterMix (No-
vagen), primers (Integrated DNA Technologies) (described in
eTable 2 [Supplement]). Next, DNAwas extracted and ampli-
fied on aMaster Cycle Pro S device (Eppendorf) using the fol-
lowing parameters: 95°C for 2 minutes, 42 cycles of 95°C for
20 seconds, and an annealing temperature as described in
eTable2 for17secondsandat70°Cfor 17seconds.Thefinalelon-
gationwasat 70°C for 20 seconds.ThePCRproductswere ana-
lyzed on agarose gels, and bands were purified with a Min-
Elute gel extraction kit (QIAGEN) if not sufficiently pure for
sequencing.Theproductsweredirectly sequenced inboth for-
ward and reverse directions in the Genewiz Laboratories. Se-
quenceoutputwasreviewedandvisuallyanalyzedfor thepres-
ence of secondary peaks indicating mutations.
Results
DNA isolated from rhomboid, negatively pigmented network
and polygonal dermoscopic growth pattern groupswerewild
typeforBRAF,NRAS,HRAS,GNAQ, andKIT.DNAisolatedfrom
thedarkhomogeneous streakspatterngrouprevealedKITmu-
tations in thecatalytic loopof thedistalkinasedomainsH790Q,
A794V, and I798M (Figure 4) (eTable 3 [Supplement]). All 3 of
these point mutations were novel. The dark homogeneous
streaks pattern group was wild type for BRAF, NRAS, HRAS,
and GNAQ.
Discussion
Dermoscopyallows forvisualizationofmelanomagrowthpat-
terns. Using a dermoscopy-based, pattern-matching ap-
proach, we have identified 3 melanoma growth patterns that
lackmutations inBRAF (exon 15),NRAS (exons 2 and3),HRAS
(exons 2 and 3), GNAQ (exon 5), and KIT (exons 11, 13, 17, and
18). Despite the high prevalence of BRAF and NRAS muta-
tions inmelanomasasawhole, all of these testedpatternswere
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wild type. This may merely be due to a selection bias, but it
is also possible that BRAF and NRAS are overrepresented in
published data sets owing to increased growth, tumor bulk
and availability, and lethality. Reports have noted that fast-
growing and vertical growth phase melanomas are more fre-
quently mutated for BRAF and NRAS.8 Ellerhorst12 et al
have shown that the median Breslow thicknesses of BRAF-
and NRAS-mutated melanomas were 1.28 mm and 1.4 mm,
respectively, whereas for wild-type melanomas the median
was 0.93 mm. Thus, it is possible that thinner and low-risk
tumors will be found to have fewer BRAF and NRAS muta-
tions than previously thought. Since the rhomboid, nega-
Figure 1. MelanomaDermoscopic Growth Patterns
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Shown are the 6 dermoscopic
patterns that were not subjected to
genetic analysis. A and B,
Disorganized fine network pattern;
the insets show a brown network
structure with irregular holes and
lines. C and D, Epidermal crease
sparing pattern; insets show
well-defined epidermal creases
surrounded by pigmented
structureless areas. E and F, Gray
dotted–regression pattern; insets
show gray dots and areas of
regression. G and H, Homogeneous
pattern; the images show light and
dark brown irregular structureless
areas. I and J, Multicolor
multicomponent pattern; the images
show light brown, dark brown, and
black colors with structureless areas,
an irregularly pigmented network,
and asymmetrical fingerlike
projections. K and L, Perifollicular
pigmented pattern; inset shows
eccentric annular pigmentation
around follicular ostia.
KITDermoscopy Pattern Case Report/Case Series Research
jamadermatology.com JAMADermatology June 2014 Volume 150, Number 6 635
Downloaded From:  by a Universidad de Barcelona User  on 03/14/2018
Copyright 2014 American Medical Association. All rights reserved.
tive, and polygonal dermoscopic patterns of melanoma did
not demonstrate common driving mutations, this pattern of
tumors could be used to identify as-yet unknownmelanoma
growth–promoting gene mutations. They may also uncover
a set of mutations that occur prior to the development of
BRAF and NRAS mutations if BRAF and NRAS mutations
occur later in progression.
Thedarkhomogeneous streakspatternwas found tohave
a specificKIT genemutation.KITmutations have been previ-
ously reported to be present in 4.3% of the cutaneous
melanomas1,4; of them, 4.4% were from exon 17, which sug-
gests that only0.19%of cutaneousmelanomaswill haveamu-
tation in exon 17. Thus, the chance that 3 out of 3melanomas
would havemutations inKIT exon 17 is 6.8 in 1 billion; there-
fore, it is rational to speculate that this specificmutationgives
rise to this specific dermoscopic growth pattern. Although all
the other cases of melanomas studied were from unique pa-
tients, it is also of interest that 2 of the dark homogeneous
streakspatternwerefromdifferentprimarytumorsonthesame
patient. While KITwas mutated in both primary tumors, the
specific mutated sequence was different, confirming the dif-
ferent originsof the 2 tumors. Patients oftenhave similarmole
patterns, and it has also been noted that patients with mul-
tiple melanomas often have tumors with similar patterns.13
Thus, it is possible that patients are predisposed to develop-
ing melanomas with mutations in specific pathways.
Our KIT-mutated tumors were dark, and this is consis-
tent with the findings of Wu et al,14 who previously reported
Figure 2. Negative Pigmented Network Pattern
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Dermoscopic images with negative
pigmented network features of the 3
melanomas (A, D, and G) with their
corresponding histologic images at
lower and highmagnifications (B, C,
E, F, H, I). All 3 have similar negative
network pattern with light areas
forming the “cords” of the network
and darker areas filling the holes
(insets). B, C, E, F, H, I:
hematoxylin-eosin; B, E, and H,
original magnification ×4, C and F,
×10, I, ×20.
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that KIT is mutated and/or overexpressed in darkly pig-
mented cutaneousmelanomas.KITmutationshavebeenpre-
viously related to a histologic lentiginous pattern present in
chronically sun-damagedareas.1Twoof theKIT-positivemela-
nomas presented hereinwere described histologically as len-
tiginous, but only 1 was in a chronically sun-damaged area.
The 3 mutations noted herein are novel and are all lo-
cated in the secondkinase domain,within or next to the cata-
lytic loop. This domain is thought to maintain the enzyme in
its active form.15 Given that KIT also has mutations in other
domains and interacts with a number of different pathways,
the different KITmutations may eventually be found to give
rise to different subsets of melanoma growth patterns.
Conclusions
In summary, one of the dermoscopic patterns, the dark
homogeneous streaks pattern, seems to correlate with KIT
mutations in or around the second kinase domain, suggest-
ing the possibility that specific growth patterns are caused
by specific driving mutations. Two of the similarly pat-
terned primary tumors occurred in the same patient, and,
while having different specific nucleotide changes, the
mutations occurred in the same domain of the same gene,
suggesting the possibility that patients may have a predis-
position to develop and/or maintain certain mutations.
Figure 3. Dark Homogeneous Streak Pattern
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Dermoscopic images with streaks and
homogeneous features of the 3
melanomas (A, D, and G) with their
corresponding histologic images at
lower and highmagnifications (B, C,
E, F, H, and I). All 3 have a similar
pattern of dark homogeneous areas
with streaks at themargins (insets).
B, C, E, F, H, I: hematoxylin-eosin; B,
E, and H, original magnification ×4, C,
F, and I, ×20.
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Three of the 4 patterns tested lacked common melanoma-
driving mutations suggesting the possibility that these pat-
terns could be used to identify other novel driving genes
and/or identify genes that are mutated in early melanoma
prior to the development of the common driving mutations.
Further study is required, but it is possible that dermoscopic
growth patterns will lead to improved molecular classifica-
tion of melanocytic neoplasias.
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